Docetaxel prolongs life in men with hormone refractory prostate cancerBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7471.877 (Published 14 October 2004) Cite this as: BMJ 2004;329:877
- Scott Gottlieb
- New York
Docetaxel (Taxotere) in combination with prednisolone helps men with advanced, hormone refractory prostate cancer live longer and enjoy more time free of pain, compared with mitoxantrone and prednisone, the current standard treatment for these patients, a US study shows.
Treatment with mitoxantrone and prednisone is known to reduce pain and improves the quality of life in men with advanced, hormone refractory prostate cancer, but it has never been shown to improve survival.
The study's researchers, led by Dr Ian Tannock from the Department of Medical Oncology and Hematology at Princess Margaret Hospital in Toronto, set out to determine whether docetaxel prolongs lives (New England Journal of Medicine 2004;354:1502-12).
The researchers …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial